LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

Search

Ionis Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

74.32 2.27

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

71.58

Max

75.6

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-100M

-229M

Pardavimai

46M

203M

Pelno marža

-112.808

Darbuotojai

1,402

EBITDA

4.7B

4.6B

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+33.69% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-04-29

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-2B

12B

Ankstesnė atidarymo kaina

72.05

Ankstesnė uždarymo kaina

74.32

Naujienos nuotaikos

By Acuity

50%

50%

167 / 350 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

Ionis Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-25 20:20; UTC

Įsigijimai, susijungimai, perėmimai

Infosys Agrees to Acquire Stratus

2026-03-25 23:58; UTC

Uždarbis

Guming Proposes 2025 Final Dividend of HK$0.50 >1364.HK

2026-03-25 23:58; UTC

Uždarbis

Guming: Seek to Further Expand Coffee Product Line, Explore New Food Categories >1364.HK

2026-03-25 23:57; UTC

Uždarbis

Guming: Aim to Expand Store Network in China, Evaluate Overseas Opportunities >1364.HK

2026-03-25 23:57; UTC

Uždarbis

Guming Store Network Rose 37% on Year to 13,554 Stores as of Dec. 31, 2025 >1364.HK

2026-03-25 23:56; UTC

Uždarbis

Guming 2025 Rev CNY12.91B Vs. CNY8.79B >1364.HK

2026-03-25 23:56; UTC

Uždarbis

Guming 2025 Net CNY3.11B Vs. Net CNY1.48B >1364.HK

2026-03-25 23:41; UTC

Rinkos pokalbiai

Nikkei May Trade Rangebound Amid Uncertainty Over U.S.-Iran Talks -- Market Talk

2026-03-25 23:41; UTC

Uždarbis

These Stocks Are Today's Movers: Arm, Intel, AMD, Firefly Aerospace, Robinhood, JD.com, Sarepta, and More -- Barrons.com

2026-03-25 23:34; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Gold Declines on Possible Technical Correction -- Market Talk

2026-03-25 22:08; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-03-25 22:08; UTC

Rinkos pokalbiai

Synlait Milk's Outlook Depends on Dunsandel -- Market Talk

2026-03-25 22:07; UTC

Uždarbis

China Mengniu Dairy: Weak Consumer Demand Weighed on Rev >2319.HK

2026-03-25 22:07; UTC

Uždarbis

China Mengniu Dairy Plans Steady Increase in Dividends For Next Three Years >2319.HK

2026-03-25 22:07; UTC

Uždarbis

China Mengniu Dairy: 2025 Net Supported by Absence of Impairment Provisions Made Last Year >2319.HK

2026-03-25 22:07; UTC

Uždarbis

China Mengniu Dairy 2025 Rev CNY82.24B Vs. CNY88.67B >2319.HK

2026-03-25 22:07; UTC

Uždarbis

China Mengniu Dairy 2025 Net CNY1.55B Vs. Net CNY104.51M >2319.HK

2026-03-25 21:58; UTC

Rinkos pokalbiai

Amplitude Energy Oversold on Isabella-1 Well Disappointment -- Market Talk

2026-03-25 21:37; UTC

Rinkos pokalbiai

Miran: AI and Deregulation Are Positive Supply Shocks To Economy -- Market Talk

2026-03-25 21:14; UTC

Įsigijimai, susijungimai, perėmimai

St Barbara: Expects to Record Gain on Sale of Roughly A$500 Million Upon Completion

2026-03-25 21:13; UTC

Įsigijimai, susijungimai, perėmimai

St Barbara: All Conditions Satisfied, Waived on Lingbao Deal

2026-03-25 21:12; UTC

Įsigijimai, susijungimai, perėmimai

Closing M&A Deals Bring Opportunity. Janus Henderson and Other Stocks to Buy. -- Barrons.com

2026-03-25 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-03-25 20:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Health Care Roundup: Market Talk

2026-03-25 20:33; UTC

Įsigijimai, susijungimai, perėmimai

KKR & Co.: Entered Agreement to Sell CoolIT Systems to Ecolab in Transaction Valued at $4.75B >KKR >KKR

2026-03-25 20:31; UTC

Uždarbis

The SpaceX IPO Is Coming. Cathie Wood's Ark Venture and More Funds to Get in on the Action. -- Barrons.com

2026-03-25 20:15; UTC

Įsigijimai, susijungimai, perėmimai

KKR Scores One of Its Best Bets With Sale of Data-Center Cooling Business -- WSJ

2026-03-25 20:15; UTC

Įsigijimai, susijungimai, perėmimai

CoolIT Employees Set to Receive Average Payouts of $240,000, Executives Say -- WSJ

2026-03-25 20:15; UTC

Įsigijimai, susijungimai, perėmimai

CoolIT Deal Ranks Among KKR's Top-4 Highest Earning Investments in Past 20 Years, Executives Say -- WSJ

2026-03-25 20:15; UTC

Įsigijimai, susijungimai, perėmimai

KKR Set to Make 15x Investment From $4.75B Sale of CoolIT to Ecolab, Executives Say -- WSJ

Akcijų palyginimas

Kainos pokytis

Ionis Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

33.69% į viršų

12 mėnesių prognozė

Vidutinis 97.19 USD  33.69%

Aukščiausias 120 USD

Žemiausias 72 USD

Remiantis 14 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ionis Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

14 ratings

11

Pirkti

3

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

29.78 / 33.645Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Neutral Evidence

Vidutinės trukmės periodas

Very Strong Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

167 / 350 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat